Log in
Mucolytic and antioxidant

Acetylcysteine

Acetylcysteine is a derivative of the amino acid cysteine that acts as a mucolytic agent and powerful antioxidant. It is most critically used as the definitive antidote for acetaminophen (paracetamol) overdose, but also treats chronic respiratory conditions and hepatic disease. The key exam fact: acetylcysteine replenishes hepatic glutathione stores, preventing toxic acetaminophen metabolite accumulation.

Practice questionsHigh-yield facts
Drug classMucolytic, antioxidant, antidote
MechanismReplenishes glutathione; breaks disulfide bonds in mucoproteins
Main usesAcetaminophen overdose, COPD, cystic fibrosis, NAC-responsive conditions
Key adverse effectNausea, bronchospasm, rash; anaphylactoid reactions possible
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Acetylcysteine is a precursor to the tripeptide glutathione (GSH), the body's primary intracellular antioxidant. It works through three main mechanisms:

  • Glutathione replenishment: Acetylcysteine is metabolized to cysteine, which is incorporated into glutathione. In acetaminophen overdose, acetaminophen is metabolized via sulfation and glucuronidation; excess acetaminophen is shunted to the cytochrome P450 pathway, forming the highly reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is normally detoxified by binding to glutathione. When glutathione is depleted, NAPQI binds to hepatocyte proteins causing hepatotoxicity. Acetylcysteine restores glutathione stores, allowing NAPQI neutralization.
  • Mucolytic action: Acetylcysteine contains a free thiol (-SH) group that breaks disulfide bonds (S-S) in mucoproteins, reducing mucus viscosity and improving clearance in airways and respiratory secretions.
  • Direct antioxidant: The free thiol group directly scavenges reactive oxygen species and free radicals, reducing oxidative stress in inflammatory conditions.
High-yield for exams
  • Acetylcysteine is the definitive antidote for acetaminophen overdose; it replenishes hepatic glutathione, allowing NAPQI detoxification.
  • Efficacy in acetaminophen overdose decreases after 10–12 hours but extends to 24 hours post-ingestion; treat all toxic levels regardless of symptoms.
  • IV acetylcysteine can trigger anaphylactoid reactions; slow infusion rates and premedication reduce risk; do not discontinue, slow the drip.
  • Acetylcysteine is a mucolytic (breaks disulfide bonds in mucus) and antioxidant (via glutathione replenishment and direct free-radical scavenging).
  • Inhaled acetylcysteine may precipitate bronchospasm in asthma; have beta-2 agonists available and consider pretreatment.
  • Acetylcysteine has no significant CYP450 interactions but may potentiate nitrates; separate from activated charcoal in overdose management.
  • Pregnancy: acetylcysteine is likely safe in acetaminophen overdose; risk of overdose toxicity outweighs uncertain teratogenic risk.

Indications

Acute acetaminophen overdose

The most critical indication. Acetylcysteine must be given within 24 hours of overdose (ideally within 8–10 hours for maximum efficacy, but still beneficial up to 24 hours). It is most effective when administered before significant hepatotoxicity occurs. Dosing follows the product label for loading dose, then maintenance phases.

Chronic respiratory diseases

Used as a mucolytic in:

  • COPD exacerbations and maintenance: Improves sputum clearance and may reduce exacerbation frequency.
  • Cystic fibrosis: Reduces mucus viscosity; often nebulized directly into airways.
  • Chronic bronchitis: Reduces sputum production and improves airway clearance.

Other clinical uses

  • Contrast-induced nephropathy: May reduce renal injury from iodinated contrast media.
  • Interstitial lung disease: Antioxidant benefit in idiopathic pulmonary fibrosis (IPF) and other ILDs.
  • Acute respiratory distress syndrome (ARDS): Antioxidant support in critical illness.
  • Polycystic kidney disease: Emerging evidence for slowing progression.
  • Sjögren syndrome: Dry eye syndrome; used topically or systemically.

Pharmacokinetics

  • Absorption: Acetylcysteine is rapidly absorbed after oral administration but undergoes extensive first-pass hepatic metabolism, resulting in low bioavailability (~5–10% unchanged). Intravenous formulations bypass this and achieve higher systemic levels. Inhaled/nebulized acetylcysteine acts locally on airways.
  • Distribution: Acetylcysteine rapidly converts to cysteine and other metabolites; cysteine is distributed widely and incorporated into proteins and glutathione. Free thiol groups allow it to penetrate cellular compartments.
  • Metabolism: Hepatic metabolism converts acetylcysteine to cysteine (via deacetylation), which is incorporated into proteins, glutathione, and taurine. Some is oxidized to diacetylcysteine and other disulfides.
  • Elimination: Metabolites are excreted renally. Half-life is approximately 5.6 hours for acetylcysteine; cysteine and derived compounds have variable kinetics.
  • Therapeutic levels: In acetaminophen overdose, plasma acetylcysteine and cysteine levels correlate with efficacy. Dosing follows the product label with attention to timing relative to overdose ingestion.

Adverse effects

Common

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramping (especially with oral formulations; often dose-limiting).
  • Respiratory: Bronchospasm, bronchorrhea (increased sputum production), dyspnea, cough (when inhaled/nebulized).
  • Dermatologic: Rash, urticaria, pruritus.

Serious and uncommon

  • Anaphylactoid reactions: Flushing, hypotension, angioedema, chest tightness. More common with IV administration, particularly if given rapidly. Often requires slowing the infusion rate or pre-treatment with antihistamines and corticosteroids. Historically thought to be "pseudoallergic," but recent data suggest true IgE-mediated mechanisms in some cases.
  • Hepatotoxicity: Paradoxically, rare cases of liver injury reported, especially with chronic oral use in susceptible individuals.
  • Hematologic: Thrombocytopenia, hemolysis (rare).
  • Ototoxicity: Hearing loss reported rarely with high-dose IV therapy.

Odor and tolerability

Oral and nebulized acetylcysteine have a strong sulfurous odor, which affects palatability and compliance. Breath and body odor may smell sulfurous.

Contraindications and warnings

Contraindications

  • History of anaphylactoid reaction to acetylcysteine: Absolute contraindication unless critical need (e.g., life-threatening acetaminophen overdose) with appropriate monitoring and premedication.
  • Severe underlying airway disease: Relative; nebulized acetylcysteine may precipitate bronchospasm; bronchodilators should be available.

Precautions

  • Anaphylactoid reactions with IV use: Risk is highest with rapid infusion or initial doses. Facilities must have resuscitation equipment available. Premedication with an antihistamine (e.g., diphenhydramine) and corticosteroid (e.g., methylprednisolone) is often used.
  • Asthma and reactive airway disease: Inhaled acetylcysteine can trigger bronchospasm; beta-2 agonists should be on hand. Consider IV route if respiratory status is compromised.
  • Pregnancy: Acetylcysteine crosses the placenta. No clear teratogenicity, but data are limited. Use only if acetaminophen overdose poses greater risk (Category B per older classification; likely safe in practice).
  • Breastfeeding: Limited data; metabolites are likely safe, but caution advised.
  • Diabetes: Acetylcysteine may reduce insulin secretion; glucose monitoring recommended.

Warnings

  • Do not mix IV acetylcysteine with other drugs in the same syringe or IV line; compatibility not established.
  • Slow IV infusion to reduce anaphylactoid reactions.
  • Cystic fibrosis patients may experience increased airway secretions; suctioning may be required.

Drug interactions

  • Acetaminophen: Acetylcysteine is the specific antidote; no adverse interaction; co-administration is therapeutic in overdose.
  • Nitroglycerin: Acetylcysteine may potentiate the hypotensive and vasodilatory effects of nitrates; blood pressure monitoring advised.
  • Activated charcoal: If charcoal is used to decontaminate in acetaminophen overdose, it may adsorb acetylcysteine. Acetylcysteine should be given after charcoal is removed, or timing should be staggered.
  • Other antioxidants: Concurrent use of high-dose vitamin E, vitamin C, or other antioxidants may have additive or unclear effects; no major contraindication, but duplication of therapy should be considered.
  • Antibiotics and other medications: Acetylcysteine is metabolically inert and does not significantly inhibit or induce cytochrome P450 enzymes. Direct pharmacokinetic interactions with other drugs are rare. However, the thiol group may interact with metal-containing compounds (e.g., iron supplements) in vitro; separate timing of administration is prudent.
  • Cisplatin and other chemotherapy: Acetylcysteine may reduce the cytotoxic efficacy of certain chemotherapy agents in some cancer patients; avoid concurrent high-dose acetylcysteine during chemotherapy unless specifically indicated.

Clinical pearls

  • Acetaminophen overdose is a medical emergency: Acetylcysteine is the life-saving antidote. The nomogram for acetaminophen toxicity determines risk and guides acetylcysteine dosing. Always check acetaminophen levels 4 hours post-ingestion if overdose is suspected; do not wait for symptoms. Fulminant hepatic failure can develop silently.
  • Timing is critical: Efficacy in acetaminophen overdose decreases after 10–12 hours post-ingestion but extends to 24 hours. Even if the patient is asymptomatic, a toxic acetaminophen level warrants treatment.
  • Anaphylactoid reactions are manageable: Slow infusion rate (over 60 minutes for loading dose instead of 15 minutes), premedication with diphenhydramine and methylprednisolone, and careful monitoring can prevent or attenuate reactions. Do not discontinue acetylcysteine; slow the infusion.
  • Respiratory uses are adjunctive: Acetylcysteine improves mucus clearance in COPD and cystic fibrosis but does not replace standard therapies (bronchodilators, chest physiotherapy, antibiotics). Evidence for clinical benefit is mixed in some conditions.
  • Nebulized acetylcysteine may trigger bronchospasm: Always have a beta-2 agonist available when inhaling acetylcysteine. Some protocols recommend giving a short-acting beta-agonist 5–15 minutes before acetylcysteine in at-risk patients.
  • NAC is increasingly used off-label: Growing evidence supports acetylcysteine in sepsis, ARDS, ILD, and other conditions characterized by oxidative stress and inflammation. Check institutional protocols.
  • Odor and compliance: The foul sulfurous smell may reduce patient adherence with oral formulations. IV or inhaled routes may be preferred for systemic delivery.
Mnemonic

NAC for APAP: N-Acetyl Cysteine for Acetaminophen overdose by replenishing Glutathione; or remember 'RESCUE' — Restores glutathione, Eliminates NAPQI, Scavenges free radicals, Clears mucus, Urgent (treat within 24 hrs), Essential antidote.

Practice questions

1. A 28-year-old woman presents to the emergency department 6 hours after ingesting 25 g of acetaminophen in a suicide attempt. Her acetaminophen level is 312 µg/mL (toxic by nomogram). Liver function tests are normal. Which of the following best explains why acetylcysteine is indicated now despite normal LFTs?

Answer: B. Acetaminophen is metabolized to N-acetyl-p-benzoquinone imine (NAPQI), a highly reactive metabolite. NAPQI is normally detoxified by binding to glutathione. In overdose, glutathione is rapidly depleted, and excess NAPQI binds to hepatocyte proteins, causing necrosis. Acetylcysteine works best before hepatocyte injury is manifest (i.e., before ALT/AST elevation and abnormal LFTs). Normal LFTs indicate that hepatocyte necrosis has not yet occurred, making this the ideal time to give acetylcysteine to prevent progression. The classic distractor is option A, which reverses cause and effect; acetylcysteine is most effective when LFTs are still normal.

2. A 52-year-old man with COPD is prescribed nebulized acetylcysteine as a mucolytic agent. Within 5 minutes of inhalation, he develops acute bronchospasm and dyspnea. Which of the following is the most appropriate immediate management?

Answer: B. Inhaled acetylcysteine can trigger bronchospasm in patients with reactive airway disease or asthma. The appropriate response is to immediately administer a short-acting beta-2 agonist (e.g., albuterol) to reverse the bronchospasm. Acetylcysteine is not contraindicated; nebulized acetylcysteine should be avoided in favor of IV or oral routes in at-risk patients, or given with pretreatment with a bronchodilator. Option A incorrectly suggests permanent discontinuation. Options C and E confuse this event with anaphylactoid reactions (which are IV-related) or overdose toxicity, which are not the issue here.

3. A 35-year-old woman with no prior allergies receives IV acetylcysteine for acetaminophen overdose. Within 15 minutes of starting the loading dose infusion, she develops flushing, pruritus, and mild dyspnea. Her blood pressure is 95/55 mm Hg (baseline 120/80). Which of the following is the most appropriate next step?

Answer: C. The patient is experiencing an anaphylactoid reaction to IV acetylcysteine, which is dose-rate dependent. The appropriate management is to SLOW the infusion rate (not stop it), administer premedications (antihistamine and corticosteroid), and continue acetylcysteine with careful monitoring. Anaphylactoid reactions are distinguished from true anaphylaxis by their predictability with rate of infusion and responsiveness to slowing the drip. Acetylcysteine is critical for acetaminophen overdose and should not be abandoned. Option B (epinephrine) is overly aggressive for an anaphylactoid reaction and is reserved for true anaphylaxis. Option E (increasing the rate) would worsen the reaction.

Frequently asked questions

How does acetylcysteine treat acetaminophen overdose?

Acetylcysteine is metabolized to cysteine and incorporated into glutathione, the body's primary antioxidant. In acetaminophen overdose, the toxic metabolite NAPQI is normally detoxified by binding to glutathione. When glutathione is depleted, NAPQI causes hepatocyte necrosis. Acetylcysteine restores glutathione, allowing NAPQI neutralization and prevention of hepatotoxicity. Efficacy is highest within 10–12 hours but extends to 24 hours post-ingestion.

What are the main side effects of acetylcysteine?

Common side effects include nausea, vomiting, and gastrointestinal upset (especially with oral formulations). Inhaled acetylcysteine may cause bronchospasm or increased sputum production. The most serious adverse effect is anaphylactoid reactions with IV administration, characterized by flushing, hypotension, and angioedema. These are manageable by slowing the infusion rate and premedication with antihistamines and corticosteroids. A strong sulfurous odor affects tolerability.

When should acetylcysteine be given in acetaminophen overdose?

Acetylcysteine should be initiated within 24 hours of acetaminophen ingestion, ideally within 8–10 hours. Timing is determined by the acetaminophen level plotted on the Rumack-Matthew nomogram at 4 hours post-ingestion. Efficacy decreases after 10–12 hours but is still beneficial through 24 hours. Treatment is indicated for all toxic levels regardless of symptoms; patients may appear well despite impending fulminant hepatic failure.

Is acetylcysteine safe in pregnancy?

Acetylcysteine crosses the placenta but has no established teratogenic effects. Limited human pregnancy data exist, but animal studies do not suggest harm. In acetaminophen overdose, the risk of untreated toxicity (fulminant hepatic failure, fetal death, maternal death) far outweighs uncertain teratogenic risk. Acetylcysteine is considered safe and indicated in pregnant women with toxic acetaminophen levels.

What is the difference between acetylcysteine's mucolytic and antioxidant roles?

As a mucolytic, acetylcysteine's free thiol group breaks disulfide bonds in mucoproteins, reducing mucus viscosity and improving airway clearance in conditions like COPD and cystic fibrosis. As an antioxidant, acetylcysteine replenishes glutathione stores and directly scavenges free radicals, reducing oxidative stress and inflammation in various conditions. Both properties are exploited clinically, with the antioxidant role being central to acetaminophen overdose treatment.

Conditions it is used for

Acetaminophen overdoseCOPDCystic fibrosisChronic bronchitisInterstitial pulmonary fibrosisAcute respiratory distress syndrome (ARDS)Contrast-induced nephropathySjögren syndrome (dry eye)
GlutathioneMesnaN-acetylcarnitineVitamin EVitamin CAlbuterol (co-therapy for bronchospasm)Ipecacuanha (older overdose management, now largely obsolete)Activated charcoal (competing decontaminant in overdose)

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R05CB01WHO ATC/DDD index: S01XA08

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.